The overall therapeutic response to the cardioprotection of SB203580 includes reduced progression of myocardial fibrosis, decreased TNFα production and down regulation of collagen Type I all of which are physiological markers whose expressions are associated with the progression of LV remodeling [126], and in the promotion of senescence and aging phenotypes. Here, TNF is linked to Myocardial fibrosis.